Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
Open Forum Infectious Diseases · 27.09.2024 · 11 (10)
DOI: 10.1093/ofid/ofae560 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 26.09.2024. Verfasst von Charlotte-Paige Rolle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Department,Orlando Immunology Center, Orlando, Florida, USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Background
In TANGO and SALSA, switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing a baseline regimen among adults who were treatment experienced, although few switched from bictegravir (B) / emtricitabine (F) / tenofovir alafenamide (TAF). Here, we present the efficacy and safety of switching to DTG/3TC as compared with continuing with B/F/TAF among adults with virologic suppression.
Methods
DYAD is an open-label clinical trial that randomized adults with HIV-1 RNA <50 copies/mL and no prior virologic failure (2:1) to switch to once-daily fixed-dose DTG/3TC or maintain B/F/TAF. The primary end point is the proportion with HIV-1 RNA ≥50 copies/mL at week 48 (Food and Drug Administration Snapshot algorithm, intention-to-treat exposed population, 6% noninferiority margin).
Results
Overall, 222 adults were randomized (16% women, 51% aged ≥50 years, 28% Black). At week 48, 6 (4%) with DTG/3TC and 5 (7%) with B/F/TAF had HIV-1 RNA ≥50 copies/mL (treatment difference, −2.8%; 95% CI, −11.4% to 3.1%), meeting noninferiority criteria. Through week 48, 18 participants (12 with DTG/3TC, 6 with B/F/TAF) met confirmed virologic withdrawal (CVW) criteria, and 2 of 18 had resistance: 1 with B/F/TAF developed M184M/I and G140G/S at week 12, and 1 with DTG/3TC had M184V at week 12. One participant with DTG/3TC and non-CVW developed M184V and K65R at week 12. Drug-related adverse events (AEs) and withdrawals due to AEs occurred in 31 (21%) and 6 (4%) participants with DTG/3TC and 2 (3%) and 0 participants with B/F/TAF, respectively.
Conclusions
Switching to DTG/3TC was noninferior to continuing B/F/TAF among adults with virologic suppression at week 48. Drug-related AEs and withdrawals were higher in the DTG/3TC arm, which is likely consistent with the open-label nature of this switch study.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Department,Orlando Immunology Center, Orlando, Florida, USA.
- Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- College of Medicine, University of Central Florida, Orlando, Florida, USA.
ORCID-Profile: Charlotte-Paige Rolle, Federico Hinestrosa
Förderung
- ViiV Healthcare
Zitieren
APA
Rolle, C. P., Castano, J., Nguyen, V., Hinestrosa, F., & DeJesus, E. (2024). Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study. Open Forum Infectious Diseases, 11(10). https://doi.org/10.1093/ofid/ofae560
Vancouver
Rolle CP, Castano J, Nguyen V, Hinestrosa F, DeJesus E. Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study. Open Forum Infectious Diseases. 2024;11(10). doi:10.1093/ofid/ofae560
BibTeX
@article{Rolle2024,
author = {Rolle, Charlotte-Paige and Castano, Jamie and Nguyen, Vu and Hinestrosa, Federico and DeJesus, Edwin},
title = {Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {10},
doi = {10.1093/ofid/ofae560}
}
EUVIMED